Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion

Irene Cossu, Gianluca Bottoni, Monica Loi, Laura Emionite, Alice Bartolini, Daniela Di Paolo, Chiara Brignole, Francesca Piaggio, Patrizia Perri, Angelina Sacchi, Flavio Curnis, Maria Cristina Gagliani, Silvia Bruno, Cecilia Marini, Alessandro Gori, Renato Longhi, Daniele Murgia, Angela Rita Sementa, Michele Cilli, Carlo TacchettiAngelo Corti, Gianmario Sambuceti, Serena Marchiò, Mirco Ponzoni, Fabio Pastorino

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Selective tumor targeting is expected to enhance drug delivery and to decrease toxicity, resulting in an improved therapeutic index. We have recently identified the HSYWLRS peptide sequence as a specific ligand for aggressive neuroblastoma, a childhood tumor mostly refractory to current therapies. Here we validated the specific binding of HSYWLRS to neuroblastoma cell suspensions obtained either from cell lines, animal models, or Schwannian-stroma poor, stage IV neuroblastoma patients. Binding of the biotinylated peptide and of HSYWLRS-functionalized fluorescent quantum dots or liposomal nanoparticles was dose-dependent and inhibited by an excess of free peptide. In animal models obtained by the orthotopic implant of either MYCN-amplified or MYCN single copy human neuroblastoma cell lines, treatment with HSYWLRS-targeted, doxorubicin-loaded Stealth Liposomes increased tumor vascular permeability and perfusion, enhancing tumor penetration of the drug. This formulation proved to exert a potent antitumor efficacy, as evaluated by bioluminescence imaging and micro-PET, leading to (i) delay of tumor growth paralleled by decreased tumor glucose consumption, and (ii) abrogation of metastatic spreading, accompanied by absence of systemic toxicity and significant increase in the animal life span. Our findings are functional to the design of targeted nanocarriers with potentiated therapeutic efficacy towards the clinical translation.

Original languageEnglish
Pages (from-to)89-99
Number of pages11
JournalBiomaterials
Volume68
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Neuroblastoma
Drug delivery
Tumors
Growth
Pharmaceutical Preparations
Peptides
Neoplasms
Animals
Toxicity
Animal Models
Cells
Bioluminescence
Cell Line
Quantum Dots
Liposomes
Capillary Permeability
Therapeutics
Refractory materials
Nanoparticles
Doxorubicin

Keywords

  • Drug delivery
  • Micro-PET
  • Neuroblastoma
  • Targeted therapy
  • Tumor penetration

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. / Cossu, Irene; Bottoni, Gianluca; Loi, Monica; Emionite, Laura; Bartolini, Alice; Di Paolo, Daniela; Brignole, Chiara; Piaggio, Francesca; Perri, Patrizia; Sacchi, Angelina; Curnis, Flavio; Gagliani, Maria Cristina; Bruno, Silvia; Marini, Cecilia; Gori, Alessandro; Longhi, Renato; Murgia, Daniele; Sementa, Angela Rita; Cilli, Michele; Tacchetti, Carlo; Corti, Angelo; Sambuceti, Gianmario; Marchiò, Serena; Ponzoni, Mirco; Pastorino, Fabio.

In: Biomaterials, Vol. 68, 01.11.2015, p. 89-99.

Research output: Contribution to journalArticle

@article{3dbe40afd37448689c2d7bd9a79cdb1b,
title = "Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion",
abstract = "Selective tumor targeting is expected to enhance drug delivery and to decrease toxicity, resulting in an improved therapeutic index. We have recently identified the HSYWLRS peptide sequence as a specific ligand for aggressive neuroblastoma, a childhood tumor mostly refractory to current therapies. Here we validated the specific binding of HSYWLRS to neuroblastoma cell suspensions obtained either from cell lines, animal models, or Schwannian-stroma poor, stage IV neuroblastoma patients. Binding of the biotinylated peptide and of HSYWLRS-functionalized fluorescent quantum dots or liposomal nanoparticles was dose-dependent and inhibited by an excess of free peptide. In animal models obtained by the orthotopic implant of either MYCN-amplified or MYCN single copy human neuroblastoma cell lines, treatment with HSYWLRS-targeted, doxorubicin-loaded Stealth Liposomes increased tumor vascular permeability and perfusion, enhancing tumor penetration of the drug. This formulation proved to exert a potent antitumor efficacy, as evaluated by bioluminescence imaging and micro-PET, leading to (i) delay of tumor growth paralleled by decreased tumor glucose consumption, and (ii) abrogation of metastatic spreading, accompanied by absence of systemic toxicity and significant increase in the animal life span. Our findings are functional to the design of targeted nanocarriers with potentiated therapeutic efficacy towards the clinical translation.",
keywords = "Drug delivery, Micro-PET, Neuroblastoma, Targeted therapy, Tumor penetration",
author = "Irene Cossu and Gianluca Bottoni and Monica Loi and Laura Emionite and Alice Bartolini and {Di Paolo}, Daniela and Chiara Brignole and Francesca Piaggio and Patrizia Perri and Angelina Sacchi and Flavio Curnis and Gagliani, {Maria Cristina} and Silvia Bruno and Cecilia Marini and Alessandro Gori and Renato Longhi and Daniele Murgia and Sementa, {Angela Rita} and Michele Cilli and Carlo Tacchetti and Angelo Corti and Gianmario Sambuceti and Serena Marchi{\`o} and Mirco Ponzoni and Fabio Pastorino",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.biomaterials.2015.07.054",
language = "English",
volume = "68",
pages = "89--99",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion

AU - Cossu, Irene

AU - Bottoni, Gianluca

AU - Loi, Monica

AU - Emionite, Laura

AU - Bartolini, Alice

AU - Di Paolo, Daniela

AU - Brignole, Chiara

AU - Piaggio, Francesca

AU - Perri, Patrizia

AU - Sacchi, Angelina

AU - Curnis, Flavio

AU - Gagliani, Maria Cristina

AU - Bruno, Silvia

AU - Marini, Cecilia

AU - Gori, Alessandro

AU - Longhi, Renato

AU - Murgia, Daniele

AU - Sementa, Angela Rita

AU - Cilli, Michele

AU - Tacchetti, Carlo

AU - Corti, Angelo

AU - Sambuceti, Gianmario

AU - Marchiò, Serena

AU - Ponzoni, Mirco

AU - Pastorino, Fabio

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Selective tumor targeting is expected to enhance drug delivery and to decrease toxicity, resulting in an improved therapeutic index. We have recently identified the HSYWLRS peptide sequence as a specific ligand for aggressive neuroblastoma, a childhood tumor mostly refractory to current therapies. Here we validated the specific binding of HSYWLRS to neuroblastoma cell suspensions obtained either from cell lines, animal models, or Schwannian-stroma poor, stage IV neuroblastoma patients. Binding of the biotinylated peptide and of HSYWLRS-functionalized fluorescent quantum dots or liposomal nanoparticles was dose-dependent and inhibited by an excess of free peptide. In animal models obtained by the orthotopic implant of either MYCN-amplified or MYCN single copy human neuroblastoma cell lines, treatment with HSYWLRS-targeted, doxorubicin-loaded Stealth Liposomes increased tumor vascular permeability and perfusion, enhancing tumor penetration of the drug. This formulation proved to exert a potent antitumor efficacy, as evaluated by bioluminescence imaging and micro-PET, leading to (i) delay of tumor growth paralleled by decreased tumor glucose consumption, and (ii) abrogation of metastatic spreading, accompanied by absence of systemic toxicity and significant increase in the animal life span. Our findings are functional to the design of targeted nanocarriers with potentiated therapeutic efficacy towards the clinical translation.

AB - Selective tumor targeting is expected to enhance drug delivery and to decrease toxicity, resulting in an improved therapeutic index. We have recently identified the HSYWLRS peptide sequence as a specific ligand for aggressive neuroblastoma, a childhood tumor mostly refractory to current therapies. Here we validated the specific binding of HSYWLRS to neuroblastoma cell suspensions obtained either from cell lines, animal models, or Schwannian-stroma poor, stage IV neuroblastoma patients. Binding of the biotinylated peptide and of HSYWLRS-functionalized fluorescent quantum dots or liposomal nanoparticles was dose-dependent and inhibited by an excess of free peptide. In animal models obtained by the orthotopic implant of either MYCN-amplified or MYCN single copy human neuroblastoma cell lines, treatment with HSYWLRS-targeted, doxorubicin-loaded Stealth Liposomes increased tumor vascular permeability and perfusion, enhancing tumor penetration of the drug. This formulation proved to exert a potent antitumor efficacy, as evaluated by bioluminescence imaging and micro-PET, leading to (i) delay of tumor growth paralleled by decreased tumor glucose consumption, and (ii) abrogation of metastatic spreading, accompanied by absence of systemic toxicity and significant increase in the animal life span. Our findings are functional to the design of targeted nanocarriers with potentiated therapeutic efficacy towards the clinical translation.

KW - Drug delivery

KW - Micro-PET

KW - Neuroblastoma

KW - Targeted therapy

KW - Tumor penetration

UR - http://www.scopus.com/inward/record.url?scp=84939637159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939637159&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2015.07.054

DO - 10.1016/j.biomaterials.2015.07.054

M3 - Article

C2 - 26276694

AN - SCOPUS:84939637159

VL - 68

SP - 89

EP - 99

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -